Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock
June 23, 2016 09:20 ET
|
Cascadian Therapeutics
SEATTLE, June 23, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced the pricing of the previously announced underwritten offering of 35,000,000 shares of its...
Cascadian Therapeutics Announces Proposed Public Offering
June 22, 2016 16:01 ET
|
Cascadian Therapeutics
SEATTLE, June 22, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced that it intends to offer and sell shares of its common stock in an underwritten public...
Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data and Outlines Key Development Strategies
June 14, 2016 06:00 ET
|
Cascadian Therapeutics
SEATTLE, June 14, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, will present clinical data from the Company’s ongoing Phase 1b studies,...
Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)
June 08, 2016 08:00 ET
|
Oncothyreon Inc.
SEATTLE, June 08, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced that the Company is changing its name to Cascadian...
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
June 05, 2016 09:00 ET
|
Cascadian Therapeutics, Inc.
CHICAGO, June 05, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of clinical data on its lead product...
Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update
May 09, 2016 16:02 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, May 09, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the...
Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016
April 19, 2016 09:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, April 19, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of data highlighting the preclinical...
Oncothyreon Appoints Scott D. Myers Chief Executive Officer
March 29, 2016 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, March 29, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products to improve the lives and...
Oncothyreon Reports Full Year and Fourth Quarter 2015 Financial Results & Provides Corporate Update
March 14, 2016 16:01 ET
|
Cascadian Therapeutics, Inc.
--Initiated Phase 2 ONT-380 Trial Based on Encouraging Combination Data-- --$56M in Cash and Investments at December 31, 2015-- SEATTLE, March 14, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc....
Oncothyreon to Present at Cowen and Company 36th Annual Health Care Conference
March 01, 2016 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, March 01, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Julie M. Eastland, President and Chief Financial Officer and Vice President, Corporate Development,...